These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 26854484)

  • 1. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
    Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
    Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
    Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
    BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Wu PY; Zhang XD; Zhu J; Guo XY; Wang JF
    Hum Pathol; 2014 Aug; 45(8):1664-73. PubMed ID: 24931464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients.
    Song G; Gu L; Li J; Tang Z; Liu H; Chen B; Sun X; He B; Pan Y; Wang S; Cho WC
    Ann Hematol; 2014 Oct; 93(10):1735-43. PubMed ID: 24858372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
    Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients.
    Lim EL; Trinh DL; Scott DW; Chu A; Krzywinski M; Zhao Y; Robertson AG; Mungall AJ; Schein J; Boyle M; Mottok A; Ennishi D; Johnson NA; Steidl C; Connors JM; Morin RD; Gascoyne RD; Marra MA
    Genome Biol; 2015 Jan; 16(1):18. PubMed ID: 25723320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance.
    Feng Y; Zhong M; Zeng S; Wang L; Liu P; Xiao X; Liu Y
    Epigenomics; 2019 Jan; 11(1):35-51. PubMed ID: 30211623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Ni H; Wang X; Liu H; Tian F; Song G
    Biomarkers; 2015; 20(4):253-7. PubMed ID: 26301883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Alencar AJ; Malumbres R; Kozloski GA; Advani R; Talreja N; Chinichian S; Briones J; Natkunam Y; Sehn LH; Gascoyne RD; Tibshirani R; Lossos IS
    Clin Cancer Res; 2011 Jun; 17(12):4125-35. PubMed ID: 21525173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.
    Nakatani F; Ferracin M; Manara MC; Ventura S; Del Monaco V; Ferrari S; Alberghini M; Grilli A; Knuutila S; Schaefer KL; Mattia G; Negrini M; Picci P; Serra M; Scotlandi K
    J Pathol; 2012 Apr; 226(5):796-805. PubMed ID: 21960059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
    Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.
    He M; Gao L; Zhang S; Tao L; Wang J; Yang J; Zhu M
    Gastric Cancer; 2014; 17(3):431-41. PubMed ID: 24232982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
    Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
    Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-21 expression predicts prognosis in diffuse large B-cell lymphoma.
    Li J; Fu R; Yang L; Tu W
    Int J Clin Exp Pathol; 2015; 8(11):15019-24. PubMed ID: 26823838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.
    Due H; Schönherz AA; Ryø L; Primo MN; Jespersen DS; Thomsen EA; Roug AS; Xiao M; Tan X; Pang Y; Young KH; Bøgsted M; Mikkelsen JG; Dybkær K
    Blood Adv; 2019 Apr; 3(7):1185-1196. PubMed ID: 30967394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and blind clinical validation of a microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL.
    Knudsen S; Hother C; Grønbæk K; Jensen T; Hansen A; Mazin W; Dahlgaard J; Møller MB; Ralfkiær E; Brown Pde N
    PLoS One; 2015; 10(2):e0115538. PubMed ID: 25692889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
    Troppan K; Wenzl K; Pichler M; Pursche B; Schwarzenbacher D; Feichtinger J; Thallinger GG; Beham-Schmid C; Neumeister P; Deutsch A
    Int J Mol Sci; 2015 Aug; 16(8):18077-95. PubMed ID: 26251897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.